NASDAQ:SCMP - (SCMP) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.00
+0.30 (1.20%)
Get New (SCMP) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCMP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (SCMP) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.00.

This chart shows the closing price for SCMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in (SCMP). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018Nomura SecuritiesReiterated RatingBuy ➝ Neutral$18.00Low
1/5/2018UBS GroupDowngradeBuy ➝ Neutral$18.00Low
1/3/2018MizuhoReiterated RatingNeutral ➝ Neutral$14.00 ➝ $18.00Low
1/2/2018SVB LeerinkReiterated RatingOutperform ➝ Market Perform$15.00Low
1/1/2018Maxim GroupDowngradeHoldLow
12/26/2017B. RileyDowngradeBuy ➝ Neutral$18.00Low
12/26/2017Maxim GroupDowngradeBuy ➝ HoldHigh
12/19/2017Nomura InstinetInitiated CoverageBuy$43.00High
12/18/2017Nomura SecuritiesInitiated CoverageBuy ➝ Buy$43.00High
12/8/2017MizuhoBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $14.00Medium
12/7/2017Maxim GroupSet Price TargetBuy$23.00Medium
12/6/2017B. RileyBoost Price TargetBuy ➝ Buy$14.00 ➝ $18.00High
11/14/2017B. RileyInitiated CoverageBuy ➝ Buy$14.00N/A
11/2/2017Maxim GroupReiterated RatingBuy$23.00N/A
11/1/2017MizuhoReiterated RatingHold$12.00N/A
10/12/2017UBS GroupLower Price TargetBuy$19.00 ➝ $15.00N/A
10/3/2017MizuhoDowngradeBuy ➝ Neutral$14.00 ➝ $12.00High
8/21/2017SVB LeerinkInitiated CoverageMarket Perform ➝ Outperform$14.00 ➝ $15.00High
8/8/2017Maxim GroupReiterated RatingBuy$21.00 ➝ $23.00Medium
8/3/2017Roth CapitalSet Price TargetBuy$30.00Medium
8/2/2017Maxim GroupSet Price TargetBuy$21.00 ➝ $23.00Medium
5/4/2017Jefferies Financial GroupLower Price TargetHold$13.00 ➝ $11.00Medium
4/20/2017Jefferies Financial GroupSet Price TargetHold$13.00Low
4/13/2017Maxim GroupReiterated RatingBuy$21.00Medium
4/4/2017MizuhoReiterated RatingBuy$14.00High
4/3/2017Maxim GroupReiterated RatingBuy$19.00 ➝ $21.00High
3/17/2017Jefferies Financial GroupLower Price TargetBuy$14.00 ➝ $13.00High
3/11/2017Maxim GroupSet Price TargetBuy$19.00Medium
3/11/2017Roth CapitalSet Price TargetBuy$27.00Medium
3/11/2017Jefferies Financial GroupReiterated RatingHold$16.00 ➝ $14.00N/A
3/11/2017UBS GroupReiterated RatingBuy$19.00N/A
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 ➝ $15.00Low
3/6/2017MizuhoReiterated RatingBuy ➝ Buy$16.00N/A
12/22/2016MizuhoUpgradeNeutral ➝ Buy$16.00N/A
11/15/2016Maxim GroupBoost Price TargetBuy$17.00 ➝ $19.00N/A
11/14/2016MizuhoBoost Price TargetNeutral$13.00 ➝ $16.00N/A
11/11/2016Jefferies Financial GroupReiterated RatingHold$14.00 ➝ $16.00N/A
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/A
8/4/2016Jefferies Financial GroupLower Price TargetHold$16.00 ➝ $14.00N/A
8/4/2016MizuhoDowngradeBuy ➝ Neutral$13.00N/A
8/1/2016Maxim GroupLower Price TargetBuy$26.00 ➝ $17.00N/A
7/12/2016Roth CapitalReiterated RatingBuyN/A
7/11/2016MizuhoReiterated RatingBuyN/A
7/11/2016Maxim GroupReiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
(SCMP) logo
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).
Read More

Today's Range

Now: $18.00
Low: $18.00
High: $18.00

50 Day Range

MA: $18.00
Low: $18.00
High: $18.00

52 Week Range

Now: $18.00
Low: $9.30
High: $18.75

Volume

303,068 shs

Average Volume

2,557,332 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (SCMP)?

The following Wall Street research analysts have issued reports on (SCMP) in the last year:
View the latest analyst ratings for SCMP.

What is the current price target for (SCMP)?

0 Wall Street analysts have set twelve-month price targets for (SCMP) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (SCMP) in the next year.
View the latest price targets for SCMP.

What is the current consensus analyst rating for (SCMP)?

(SCMP) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SCMP.

What other companies compete with (SCMP)?

How do I contact (SCMP)'s investor relations team?

(SCMP)'s physical mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company's listed phone number is +1-301-9613400 and its investor relations email address is [email protected] The official website for (SCMP) is www.sucampo.com.